{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:00:21Z","timestamp":1773392421187,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1678,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Center for Companion Animal Health (CCAH), School of Veterinary Medicine, University of California\u2014Davis, Davis, CA, USA","award":["CCAH 2017-75-F"],"award-info":[{"award-number":["CCAH 2017-75-F"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Safe, effective, and readily available drug therapies are required for the management of hyperlipidemia and its associated complications in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the efficacy of a micronized, nanocrystal formulation of fenofibrate (Tricor) in the treatment of hyperlipidemia in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Ten client-owned dogs with primary (n\u00a0=\u00a07) and secondary (n\u00a0=\u00a03) hyperlipidemia. All dogs had hypertriglyceridemia at baseline; 3 dogs also had hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective dose-escalation study. Dogs were treated with fenofibrate orally once daily in up to 3\u00a0cycles of 21\u2009days each. Fenofibrate dose was increased at the end of each cycle if hypertriglyceridemia persisted and adverse effects were not documented. Complete blood count, biochemistry, and urine protein:creatinine ratio were collected serially. Baseline (T0) parameters were compared to time of maximal reduction in serum triglyceride concentrations (T1) and reported as median (range).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Triglycerides normalized in all dogs (T0\u00a0=\u00a0662\u2009mg\/dL [189-2391]; T1\u00a0= 113\u2009mg\/dL [81-132]; P\u00a0=\u00a0.002). Fenofibrate dose at T1\u00a0=\u00a06.4\u00a0mg\/kg PO q24h (range, 2.2-13.5). T1 was achieved at 3 (n\u00a0=\u00a04), 6 (n\u00a0=\u00a04), and 9 (n\u00a0=\u00a02) weeks. Serum cholesterol concentrations decreased in 9 of 10 dogs. Quiet demeanor and firm stools in 1 dog were the only reported adverse reactions. Fenofibrate administration resulted in a significant reduction in median alkaline phosphatase activity (P\u00a0=\u00a0.049).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Over 21 to 63\u2009days, TriCor was effective in the management of primary and secondary hyperlipidemia in dogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16190","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T08:38:22Z","timestamp":1623055102000},"page":"1733-1742","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-5915","authenticated-orcid":false,"given":"Matthew J. L.","family":"Munro","sequence":"first","affiliation":[{"name":"Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California\u2014Davis , 1 Garrod Drive, Davis, California 95616,","place":["USA"]},{"name":"The Melbourne Veterinary School, University of Melbourne Department of Veterinary Clinical Sciences, , 250 Princes Highway, Werribee, Victoria 3030,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean E.","family":"Hulsebosch","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California\u2014Davis Department of Medicine and Epidemiology, , 1 Shields Ave., Davis, California 95616,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7991-702X","authenticated-orcid":false,"given":"Stanley L.","family":"Marks","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California\u2014Davis Department of Medicine and Epidemiology, , 1 Shields Ave., Davis, California 95616,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0393-4135","authenticated-orcid":false,"given":"Chen","family":"Gilor","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California\u2014Davis Department of Medicine and Epidemiology, , 1 Shields Ave., Davis, California 95616,","place":["USA"]},{"name":"College of Veterinary Medicine, University of Florida Department of Small Animal Clinical Sciences, , 2560 SE 16th Ave., Gainesville, Florida 32610,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2026020922180175100_jvim16190-bib-0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tvjl.2008.10.011","article-title":"Lipid metabolism and hyperlipidemia in dogs","volume":"183","author":"Xenoulis","year":"2010","journal-title":"Vet J"},{"key":"2026020922180175100_jvim16190-bib-0002","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1939-1676.2007.tb01942.x","article-title":"Investigation of hypertriglyceridemia in healthy Miniature Schnauzers","volume":"21","author":"Xenoulis","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1746-6148-9-47","article-title":"Novel lipoprotein density profiling in healthy dogs of various breeds, healthy Miniature Schnauzers, and Miniature Schnauzers with hyperlipidemia","volume":"9","author":"Xenoulis","year":"2013","journal-title":"BMC Vet Res"},{"key":"2026020922180175100_jvim16190-bib-0004","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.rvsc.2009.12.003","article-title":"Predisposition for primary hyperlipidemia in Miniature Schnauzers and Shetland Sheepdogs as compared to other canine breeds","volume":"88","author":"Mori","year":"2010","journal-title":"Res Vet Sci"},{"key":"2026020922180175100_jvim16190-bib-0005","article-title":"Canine and Feline Endocrinology","author":"Feldman","year":"2015","edition":"4"},{"key":"2026020922180175100_jvim16190-bib-0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0009-8981(77)90275-3","article-title":"Plasma lipoprotein changes in experimental cholestasis in the dog","volume":"80","author":"Danielsson","year":"1977","journal-title":"Clin Chim Acta"},{"key":"2026020922180175100_jvim16190-bib-0007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5326\/15473317-32-4-313","article-title":"Clinical and pathological features of protein-losing glomerular disease in the dog: a review of 137 cases (1985-1992)","volume":"32","author":"Cook","year":"1996","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020922180175100_jvim16190-bib-0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2460\/javma.1999.214.01.46","article-title":"Evaluation of risk factors for fatal acute pancreatitis in dogs","volume":"214","author":"Hess","year":"1999","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0009","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2460\/javma.1993.203.05.673","article-title":"Risk factors associated with acute pancreatitis in dogs: 101 cases (1985-1990)","volume":"203","author":"Cook","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1939-1676.2010.0644.x","article-title":"Serum triglyceride concentrations in Miniature Schnauzers with and without a history of probable pancreatitis","volume":"25","author":"Xenoulis","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0011","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2460\/ajvr.2005.66.81","article-title":"Influence of obesity on plasma lipid and lipoprotein concentrations in dogs","volume":"66","author":"Jeusette","year":"2005","journal-title":"Am J Vet Res"},{"key":"2026020922180175100_jvim16190-bib-0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2460\/javma.231.1.79","article-title":"Gallbladder disease in Shetland Sheepdogs: 38 cases (1995-2005)","volume":"231","author":"Aguirre","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0013","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5326\/0460229","article-title":"Association between serum triglyceride and canine pancreatic lipase immunoreactivity concentrations in Miniature Schnauzers","volume":"46","author":"Xenoulis","year":"2010","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020922180175100_jvim16190-bib-0014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tvjl.2013.10.019","article-title":"The association between gallbladder mucoceles and hyperlipidemia in dogs: a retrospective case control study","volume":"199","author":"Kutsunai","year":"2014","journal-title":"Vet J"},{"key":"2026020922180175100_jvim16190-bib-0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5326\/JAAHA-MS-6791","article-title":"Evaluation of hypertriglyceridemia as a mediator between endocrine diseases and pancreatitis in dogs","volume":"55","author":"Kim","year":"2019","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020922180175100_jvim16190-bib-0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2460\/javma.232.1.63","article-title":"Serum liver enzyme activities in healthy Miniature Schnauzers with and without hypertriglyceridemia","volume":"232","author":"Xenoulis","year":"2008","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0017","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2460\/javma.238.8.1011","article-title":"Association of hypertriglyceridemia with insulin resistance in healthy Miniature Schnauzers","volume":"238","author":"Xenoulis","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0018","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tvjl.2016.04.009","article-title":"Proteinuria and lipoprotein lipase activity in Miniature Schnauzer dogs with and without hypertriglyceridemia","volume":"212","author":"Furrow","year":"2016","journal-title":"Vet J"},{"key":"2026020922180175100_jvim16190-bib-0019","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/0300985816681412","article-title":"Glomerular lesions in proteinuric Miniature Schnauzers","volume":"54","author":"Furrow","year":"2017","journal-title":"Vet Pathol"},{"key":"2026020922180175100_jvim16190-bib-0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0300985817709889","article-title":"Glomerular lipidosis in dogs","volume":"54","author":"Kohnken","year":"2017","journal-title":"Vet Pathol"},{"key":"2026020922180175100_jvim16190-bib-0021","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/jvim.14833","article-title":"Clinical consequences of hypertriglyceridemia-associated proteinuria in Miniature Schnauzers","volume":"31","author":"Smith","year":"2017","journal-title":"Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1748-5827.1993.tb03522.x","article-title":"Ocular manifestations of hyperlipoproteinemia","volume":"34","author":"Crispin","year":"1993","journal-title":"J Small Anim Pract"},{"key":"2026020922180175100_jvim16190-bib-0023","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/j.1939-1676.2007.tb01954.x","article-title":"Neurologic dysfunction in hypothyroid, hyperlipidemic Labrador Retrievers","volume":"21","author":"Vitale","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0024","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1939-1676.2003.tb02469.x","article-title":"Association between diabetes mellitus, hypothyroidism, or hyperadrenocorticism, and atherosclerosis in dogs","volume":"17","author":"Hess","year":"2003","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0025","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/jvim.15880","article-title":"Effect of a low-fat diet on serum triglyceride concentrations and lipoprotein profiles in Miniature Schnauzers with hypertriglyceridemia","volume":"34","author":"Xenoulis","year":"2020","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0026","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"2026020922180175100_jvim16190-bib-0027","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.clinthera.2015.09.001","article-title":"Nonstatin therapies for management of dyslipidemia: a review","volume":"37","author":"Sando","year":"2015","journal-title":"Clin Ther"},{"key":"2026020922180175100_jvim16190-bib-0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/jrms.JRMS_772_19","article-title":"Fenofibrate-induced renal dysfunction, yes or no?","volume":"25","author":"Emami","year":"2020","journal-title":"J Res Med Sci"},{"key":"2026020922180175100_jvim16190-bib-0029","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2460\/javma.1995.206.11.1684","article-title":"Evaluation and dietary considerations in idiopathic hyperlipidemia in dogs","volume":"206","author":"Bauer","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922180175100_jvim16190-bib-0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jvim.14701","article-title":"Therapy of canine hyperlipidemia with bezafibrate","volume":"31","author":"De Marco","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0031","doi-asserted-by":"crossref","first-page":"106578","DOI":"10.1016\/j.domaniend.2020.106578","article-title":"Fenofibrate treatment for severe hypertriglyceridemia in dogs","volume":"74","author":"Miceli","year":"2021","journal-title":"Domest Anim Endocrinol"},{"key":"2026020922180175100_jvim16190-bib-0032","article-title":"U.S. Food & Drug Administration Drug Database [Internet]","year":"2020"},{"key":"2026020922180175100_jvim16190-bib-0033","first-page":"47","article-title":"A review of currently available fenofibrate and fenofibric acid formulations","volume":"4","author":"Ling","year":"2013","journal-title":"Cardiol Res"},{"key":"2026020922180175100_jvim16190-bib-0034","doi-asserted-by":"crossref","first-page":"2037S","DOI":"10.1093\/jn\/136.7.2037S","article-title":"Fenofibrate lowers lipid parameters in obese dogs","volume":"136","author":"Serisier","year":"2006","journal-title":"J Nutr"},{"key":"2026020922180175100_jvim16190-bib-0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1254\/jphs.FP0072346","article-title":"Antidiabetic and hypolipidemia effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha\/gamma agonist, E3030, in db\/db mice and beagle dogs","volume":"108","author":"Kasai","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"2026020922180175100_jvim16190-bib-0036","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/VHRM.S3390","article-title":"Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing","volume":"4","author":"Farnier","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"2026020922180175100_jvim16190-bib-0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00003495-199754040-00007","article-title":"Micronized fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia","volume":"54","author":"Adkins","year":"1997","journal-title":"Drugs"},{"key":"2026020922180175100_jvim16190-bib-0038","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2165\/00003495-200262130-00013","article-title":"Micronized fenofibrate: an updated review of its clinical efficacy in the management of dyslipidemia","volume":"62","author":"Keating","year":"2002","journal-title":"Drugs"},{"issue":"4","key":"2026020922180175100_jvim16190-bib-0039","article-title":"Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: real-world results and factors associated with triglyceride reduction","volume":"13","author":"Woo","year":"2018","journal-title":"PLoS One"},{"key":"2026020922180175100_jvim16190-bib-0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2026020922180175100_jvim16190-bib-0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"Christian","year":"2014","journal-title":"Am J Med"},{"key":"2026020922180175100_jvim16190-bib-0042","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s10620-017-4812-7","article-title":"Identification and characterization of fenofibrate-induced liver injury","volume":"62","author":"Ahmad","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2026020922180175100_jvim16190-bib-0043","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","article-title":"Combined therapy in the treatment of dyslipidemia","volume":"24","author":"Reiner","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"2026020922180175100_jvim16190-bib-0044","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"2026020922180175100_jvim16190-bib-0046","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart","year":"2002","journal-title":"Nephron"},{"key":"2026020922180175100_jvim16190-bib-0047","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vph.2006.01.004","article-title":"Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1","volume":"44","author":"Chen","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"2026020922180175100_jvim16190-bib-0048","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1258\/ebm.2009.009218","article-title":"Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1\/Smad3 in diabetic nephropathy","volume":"235","author":"Li","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026020922180175100_jvim16190-bib-0049","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1023\/A:1005661516165","article-title":"Fatty infiltration of liver in hyperlipidemic patients","volume":"45","author":"Assy","year":"2000","journal-title":"Dig Dis Sci"},{"key":"2026020922180175100_jvim16190-bib-0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jvim.14872","article-title":"Comparison of single, averaged, and pooled urine protein:creatinine ratios in proteinuric dogs undergoing medical treatment","volume":"32","author":"Shropshire","year":"2018","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0051","first-page":"425","article-title":"Day-to-day variation in urine protein:creatinine ratio in female dogs with stable glomerular proteinuria caused by X-linked hereditary nephropathy","volume":"21","author":"Nabity","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020922180175100_jvim16190-bib-0052","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0014-5793(01)02146-9","article-title":"Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats","volume":"491","author":"Mancini","year":"2001","journal-title":"FEBS Lett"},{"key":"2026020922180175100_jvim16190-bib-0053","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.metabol.2004.05.003","article-title":"Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL\/6J mice","volume":"53","author":"Jeong","year":"2004","journal-title":"Metabolism"},{"key":"2026020922180175100_jvim16190-bib-0054","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5414\/CPP44064","article-title":"Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation","volume":"44","author":"Sauron","year":"2006","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1733\/66651539\/jvim16190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/4\/1733\/66651539\/jvim16190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:29:48Z","timestamp":1770694188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/4\/1733\/8446923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16190","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"2020-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}